Trevi Therapeutics (TRVI) Stock Price, News & Analysis

Company Overview

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for conditions involving chronic cough and other debilitating symptoms for which available treatment options are limited. The company’s lead product candidate is Haduvio, an extended-release formulation of nalbuphine, an opioid receptor modulator being investigated as a potential treatment for chronic cough.

Trevi is evaluating Haduvio for chronic cough associated with idiopathic pulmonary fibrosis (IPF), a progressive lung disease, as well as refractory chronic cough, which persists despite treatment of underlying conditions. The company has conducted clinical studies to assess the therapy’s ability to reduce cough frequency and severity and continues to advance its development through late-stage clinical programs. Haduvio is investigational and has not been approved for commercial use.

Trevi Therapeutics was founded in 2011 and is headquartered in New Haven, Connecticut. The company’s activities are primarily focused on clinical development and regulatory advancement in the United States and other markets where it conducts clinical research. Trevi is led by President and Chief Executive Officer Jennifer Good.

Key Stats

• Today's Range: $13.51 to $14.11
• 50-Day Range: $13.91 to $18.84
• 52-Week Range: $9.28 to $20.22
• Volume: 886,043 shs
• Average Volume: 1.71 million shs
• Market Capitalization: $1.95 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $27.08
• Consensus Rating: Buy

Trevi Therapeutics Stock Analysis - MarketRank™

Trevi Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 556th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Trevi Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Trevi Therapeutics has a consensus price target of $27.08, representing about 98.6% upside from its current price of $13.64.

Amount of Analyst Coverage

Trevi Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Trevi Therapeutics are expected to decrease in the coming year, from ($0.48) to ($0.62) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Trevi Therapeutics is -40.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Trevi Therapeutics is -40.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Trevi Therapeutics has a P/B Ratio of 9.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.01% of the float of Trevi Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Trevi Therapeutics has a short interest ratio ("days to cover") of 8.79.

Change versus previous month

Short interest in Trevi Therapeutics has recently increased by 0.48%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Trevi Therapeutics does not currently pay a dividend.

Dividend Growth

Trevi Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

4 people have added Trevi Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Trevi Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $595,648.00 in company stock.

Percentage Held by Insiders

15.39% of the stock of Trevi Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

95.76% of the stock of Trevi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/05/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:TRVI
• CIK: 1563880
• Web: www.trevitherapeutics.com
• Phone: (203) 304-2499
• Fax: N/A
• Employees: 34
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Trevi Therapeutics: $27.08
• High Price Target: $40.00
• Low Price Target: $16.00
• Potential Upside/Downside: +98.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$42.76 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -23.59%
• Return on Assets: -22.64%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 37.28
• Quick Ratio: 37.28

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.43 per share
• Price / Book: 9.56

Miscellaneous

• Outstanding Shares: 142,480,000
• Free Float: 120,549,000
• Market Cap: $1.95 billion
• Optionable: Optionable
• Beta: 0.98